SAN DIEGO, Dec. 21, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced earlier today with Astellas Pharma US, Inc. (Astellas), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo:4503) that the co-promotion of SUMAVEL DosePro (sumatriptan injection) Needle-free Delivery System currently in place will end on March 31, 2012. SUMAVEL DosePro (sumatriptan injection) Needle-free Delivery System, was launched with Astellas in January 2010 for the acute treatment of migraine and cluster headache. Beginning in the second quarter of 2012, Zogenix will assume full responsibility for the continued commercialization of the brand, with a focus on headache specialists, neurologists and primary care physicians who treat a significant number of migraine patients. Zogenix is also evaluating potential co-promotion partners who could complement the Zogenix sales force efforts.
